About Medis

About Medis: our story

About Medis. Medis was created in 1989 as a spin-off of the Leiden University Medical Centre (LUMC Netherlands). Our founder and current CSO, Hans Reiber, built the company focusing on X-ray and image analysis of the heart with the mission to make these tools available to all medical researchers and specialists.

For over 30 years, Medis has been providing high-quality quantitative analysis solutions for cardiovascular imaging to the medical community. Our heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to cardiologists, radiologists, researchers, and industry partners.

Medis’ software is internationally appreciated due to its ease of use, and due to the clinical outcome for the patients. Our software creation and realization process is as simple, as it is unique: starting from a medical need that develops from concept to product. We continue to create, research, and innovate toward clinically relevant software solutions in cardiovascular imaging. In Medis, this continuous innovation leads to new software solutions based on new ideas for the ever-changing cardiovascular imaging environment.

And at the same time, we remain relevant socially and sustainably. At Medis, quality is key. We test and validate in the most optimal way and deliver software solutions of the highest quality, without compromise…

That is what we have been doing for the last 30 years.

Our vision and purpose.


“To be our customers’ and partners’ first choice in cardiovascular imaging solutions, while being the employer where we feel valued for our contribution to the Medis solutions at all levels of the organization.”


“Our purpose is to improve patients’ lives by empowering medical professionals with the ultimate cardiovascular imaging solutions.”

Our values

Customers 1st

We set higher standards and expectations to create the best experience for our partners and customers.


Reliability and commitment are at the core of what we do, we keep our promises and we honor our commitments to partners, customers and to each other.


We work together, and we strive to improve our processes continuously by recognizing and appreciating the contributions and accomplishments of our team members.​


We work in a transparent way and we are focused on open and honest communication.​


Who we work with

The management Team

Maya Barley

Maya joined Medis in early 2023 as Chief Product Officer and is appointed CEO as of August 2023. She brings over 15 years’ experience in leadership, product management and innovation positions across a broad range of companies in the medical device space including Philips, Keeler, and LumiraDx. Maya is passionate about working at the clinical-technical-business interface, understanding workflows and trends, and using those insights to drive healthcare business strategy, product development, and clinical studies in multi-national environments. She has a PhD from the Harvard-MIT Division of Health Sciences and Technology and an MSc in Electrical Engineering from MIT.

Johan (Hans) HC Reiber

Hans is co-founder and former CEO of Medis. He is also founder of the Division of Image Processing (LKEB), initially at the Thoraxcenter in Rotterdam and later at the Leiden University Medical Center (LUMC). He is emeritus professor for cardiovascular imaging both at the LUMC and the Interuniversity Cardiology Institute of the Netherlands (ICIN) and member of the Royal Netherlands Academy of Arts and Sciences (KNAW). Hans’ ambition has always been to bring innovative image-based quantitation applications into the hands of the clinicians and clinical researchers worldwide. Hans now serves as Chief Scientific Officer, heading Applied Research and is the primary point-of-contact for internal and external clinical research trials.

André van Zijdveld


André van Zijdveld


the Supervisory Board

Dharminder Chahal

Dharminder Chahal is owner and managing director of Exponential B.V. in which capacity he acts as consultant to Van Herk Investments and companies in the Van Herk Investments portfolio. Furthermore he is CEO and co-founder of SkylineDx a company based in Rotterdam, The Netherlands, and developing diagnostic tests in oncology. Mr. Chahal has built an extensive network in the global life science industry and created a strong track record in supporting successful companies in their journeys. Currently the main investments in the portfolio are Galapagos, Zealand Pharma (Denmark) and BioInvent (Sweden). As a board member or advisor he has been and still is active for several European companies and funds in the field of life sciences. Mr. Chahal previously held various positions in investment banking and asset management, including Kempen & Co and Robeco. Mr. Chahal obtained a master degree in Business Economics (Erasmus University Rotterdam) and a master degree cum laude in Aerospace Engineering (TU Delft).

Carl J.G. Evertsz

Before joining Medis’ supervisory board in 2018, Carl Evertsz consulted Medis in the areas of business and corporate development and corporate finance. Carl has extensive experience founding, leading, and growing innovative medical imaging companies. He actively led international business, corporate and R&D developments, including M&A and technology acquisitions. Amongst others, he was CEO of MeVis Medical Solutions AG, which he led through a successful IPO in 2007, and CEO of MeVis BreastCare, a joint-venture with Siemens founded in 2001. As business angel he served 4 years at SCiLS GmbH as chairman of the advisory board and since 2014 at ScreenPoint Medical B.V. as a non-executive member of the board of directors.

Pieter de Wit

In various international roles, Pieter fosters the development of small and medium-sized businesses and scale-ups. Currently, Pieter is CFO at DPD Belgium and Luxemburg, which is doubling its revenues in three years and investing more than 60m€ in its infrastructure. At TNT, Pieter has also been responsible for the venture capital activities, holding various board roles in Europe and the US. Other past management roles include CEO of TNT Innight as well as director planning and control of TNT Group. As a consultant, Pieter has extensive experience in corporate strategy and M&A, among others at McKinsey & Co and Kempen &Co. He lectures on financial topics, e.g., in corporate valuation at the Rotterdam School of Management.